Skip to main content
Erschienen in: Pediatric Cardiology 5/2010

01.07.2010 | Original Article

Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension

verfasst von: Robyn J. Barst, Gabriella Agnoletti, Alain Fraisse, James Baldassarre, David L. Wessel, For the NO Diagnostic Study Group

Erschienen in: Pediatric Cardiology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to determine whether a combination of inhaled nitric oxide (iNO) and O2 is more effective than 100% O2 or iNO alone for acute vasodilator testing in children. An open, prospective, randomized, controlled trial was conducted at 16 centers. Subjects were children 4 weeks to 18 years of age with pulmonary hypertension (PH) and increased pulmonary vascular resistance (PVR) undergoing right heart catheterization for acute vasodilator testing. All patients were tested with each of three agents (80 ppm iNO, 100% O2, combination of 80 ppm iNO/100% O2) in three 10-min treatment periods, and hemodynamic measurements obtained. Primary outcome measures were percentages of acute responders with O2 alone vs. iNO/O2 and iNO alone vs. iNO/O2. More patients on the combination were acute responders compared with O2 or iNO alone (26% vs. 14%, P = 0.019, and 27% vs. 24%, P = 0.602, respectively). Changes in PVR index and mean pulmonary arterial pressure vs. baseline were greater with iNO/O2 vs. either O2 or iNO alone (P < 0.001). Survival at 1-year follow-up included (1) 90.9% of acute responders to the combination, compared with 77.8% of nonresponders to the combination, and (2) 85.7% of acute responders to O2 alone, compared with 80.6% of nonresponders to O2. Key conclusions are as follows. In children with PH and increased PVR, more acute responders were identified with the iNO/O2 combination vs. O2 alone. While there was no significant difference in acute responder rate with iNO alone vs. iNO/O2, the combination improved pulmonary hemodynamics acutely better than iNO alone. One-year survival data show similar rates between the iNO/O2 and the O2 alone groups; however, the combination may be more effective than O2 alone in discriminating survivors versus nonsurvivors at long-term follow-up.
Literatur
1.
Zurück zum Zitat Atz AM, Adatia I, Lock JE, Wessel DL (1999) Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33:813–819CrossRefPubMed Atz AM, Adatia I, Lock JE, Wessel DL (1999) Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33:813–819CrossRefPubMed
2.
Zurück zum Zitat Badesch DB, Champion HC, Gomez-Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66CrossRefPubMed Badesch DB, Champion HC, Gomez-Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66CrossRefPubMed
3.
Zurück zum Zitat Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 106(12; Suppl 1):I76–I81PubMed Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 106(12; Suppl 1):I76–I81PubMed
4.
Zurück zum Zitat Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78–S84CrossRefPubMed Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78–S84CrossRefPubMed
5.
Zurück zum Zitat Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197–1208PubMed Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197–1208PubMed
6.
Zurück zum Zitat Barst RJ (1986) Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest 89:497–503CrossRefPubMed Barst RJ (1986) Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest 89:497–503CrossRefPubMed
7.
Zurück zum Zitat Bennett D, Marcus R, Stokes M (2005) Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 15:1083–1088PubMed Bennett D, Marcus R, Stokes M (2005) Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 15:1083–1088PubMed
8.
Zurück zum Zitat Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ (2001) Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 119:128–136CrossRefPubMed Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ (2001) Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 119:128–136CrossRefPubMed
9.
Zurück zum Zitat Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493–2537CrossRefPubMed Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493–2537CrossRefPubMed
10.
Zurück zum Zitat Houde C, Bohn DJ, Freedom RM, Rabinovitch M (1993) Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 70:461–468CrossRefPubMed Houde C, Bohn DJ, Freedom RM, Rabinovitch M (1993) Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 70:461–468CrossRefPubMed
11.
Zurück zum Zitat Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366–375PubMed Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366–375PubMed
12.
Zurück zum Zitat Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36:2204–2211CrossRefPubMed Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36:2204–2211CrossRefPubMed
13.
Zurück zum Zitat Marshall HW, Swan HJ, Burchell HB, Wood EH (1961) Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 23:241–252PubMed Marshall HW, Swan HJ, Burchell HB, Wood EH (1961) Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 23:241–252PubMed
14.
Zurück zum Zitat McLaughlin VM, Archer SA, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA (2009) ACCF/AHA clinical expert consensus document on pulmonary hypertension. Circulation 119:2250–2294CrossRefPubMed McLaughlin VM, Archer SA, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA (2009) ACCF/AHA clinical expert consensus document on pulmonary hypertension. Circulation 119:2250–2294CrossRefPubMed
15.
Zurück zum Zitat Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225–234CrossRefPubMed Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225–234CrossRefPubMed
16.
Zurück zum Zitat Pagano D, Townend JN, Horton R, Smith C, Clutton-Brock T, Bonser RS (1996) A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10:1120–1126CrossRefPubMed Pagano D, Townend JN, Horton R, Smith C, Clutton-Brock T, Bonser RS (1996) A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10:1120–1126CrossRefPubMed
17.
Zurück zum Zitat Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173–1174CrossRefPubMed Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173–1174CrossRefPubMed
18.
Zurück zum Zitat Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMedCrossRef Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMedCrossRef
19.
Zurück zum Zitat Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM (1993) Inhaled nitric oxide in congenital heart disease. Circulation 87:447–453PubMed Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM (1993) Inhaled nitric oxide in congenital heart disease. Circulation 87:447–453PubMed
20.
Zurück zum Zitat Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl 1):7S–10SCrossRefPubMed Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl 1):7S–10SCrossRefPubMed
21.
Zurück zum Zitat Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151(2; Pt 1):384–389PubMed Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151(2; Pt 1):384–389PubMed
22.
Zurück zum Zitat Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270CrossRefPubMed Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270CrossRefPubMed
23.
Zurück zum Zitat Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111CrossRefPubMed Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111CrossRefPubMed
24.
Zurück zum Zitat Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR (2007) Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 98:657–661CrossRefPubMed Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR (2007) Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 98:657–661CrossRefPubMed
25.
Zurück zum Zitat Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660–665CrossRefPubMed Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660–665CrossRefPubMed
Metadaten
Titel
Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension
verfasst von
Robyn J. Barst
Gabriella Agnoletti
Alain Fraisse
James Baldassarre
David L. Wessel
For the NO Diagnostic Study Group
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 5/2010
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-010-9645-5

Weitere Artikel der Ausgabe 5/2010

Pediatric Cardiology 5/2010 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.